AMAnas Mansour

Anas Mansour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anas Mansour has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment

    by Yehia Nabil, Ahmed Shaheen, Anas Mansour, Enas Kamal Abdalaziz Seyed, Baraah abu Alsel, Safya E. Esmaeel, Mostafa Meshref, Ram Saha

  • Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis

    by Rida Shakeel, Ammad Uddin, Diksha Ladhani, Khubaib Tariq Mansoor, Anas Mansour, Bibi Zarfeen Talpur, Muhammad Hasnain Azeem, Alishba Fatima, Emad Uddin Sajid, Sohaib Aftab Ahmad Chaudhry, et al.

    Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.

  • Open Access

    Diagnostic Accuracy of 12‐Lead ECG Algorithms for Accessory Pathway Localization in WPW: A Meta‐Analysis

    by Elsayed S. Moubarak, Ahmed Farid Gadelmawla, Almothana Manasrah, Anas Mansour, Mohamed S. Elgendy, Omar Elkoumi, Husam Abu Suilik, Suhaib El Khatib, Naser Albekaen, Ahmed Moustafa, et al.

    Background: In Wolff–Parkinson–White (WPW) syndrome, accurate localization of accessory pathways before catheter ablation can improve procedural planning and efficiency. Several 12‐lead electrocardiographic (ECG) algorithms have been proposed, but their diagnostic performance has not been consistently established. We performed a systematic review and meta‐analysis to assess the accuracy of ECG‐based algorithms for accessory pathway localization in manifest WPW. Methods: Following PRISMA‐DTA recommendations, PubMed, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus were searched from January 1990 to January 2026. Studies enrolling adult or pediatric patients with manifest pre‐excitation who underwent electrophysiological study (EPS) and catheter ablation were included. Successful localization during EPS/ablation served as the reference standard. Random‐effects models were used to calculate pooled diagnostic accuracy, sensitivity, specificity, and diagnostic odds ratios (DOR). Summary receiver operating characteristic and leave‐one‐out sensitivity analyses were also performed. Results: Seventeen studies involving 3159 patients met inclusion criteria. The pooled diagnostic accuracy of ECG algorithms was 0.91 (95% CI 0.85–0.94), although heterogeneity was substantial (I 2 = 91.4%). Pooled sensitivity was 0.87 (95% CI 0.73–0.94), and pooled specificity was 0.98 (95% CI 0.95–0.99; I 2 = 0%). The pooled DOR was 297.17 (95% CI 46.33–1906.19; p <0.0001). Sensitivity analyses showed stable results after sequential exclusion of individual studies. Conclusion: Twelve‐lead ECG algorithms provide high diagnostic performance for accessory pathway localization in manifest WPW and may be useful adjuncts for pre‐ablation planning, although invasive electrophysiological mapping remains essential.

  • Safety and efficacy of early antiplatelet therapy after intravenous thrombolysis for acute ischemic stroke: A comprehensive meta-analysis with trial sequential analysis

    by Hamdy A. Makhlouf, Ahmed Harb, Moaz Elsayed Abouelmagd, Anas Mansour, Ahmed S.A. Osman, Nada Mosad, Ahmed H. Abdelaal, Omar Kassar, Jeffrey L. Saver

    Background: Early antiplatelet therapy after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients may prevent re-occlusion and early neurological deterioration, but it could increase hemorrhagic transformation. Evidence remains conflicting, particularly with emerging contemporary trials. Methods: We conducted a Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guided systematic review of randomized controlled trials (RCTs) comparing early antiplatelet therapy (eAPT) initiated within 24 h after IVT (with or without thrombectomy) versus standard timing (>24 h), placebo, or no antiplatelet therapy (CRD420251276445). Random-effects models were used to estimate odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs). Trial sequential analysis, subgroup analyses, meta-regression, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty ratings were performed. Results: Twelve RCTs with 4595 patients were included. Early antiplatelet therapy led to higher non-significant odds of symptomatic intracranial hemorrhage (sICH; OR = 1.68, 95% CI = 0.94–3.01; I 2 = 10.4%; GRADE moderate), and mortality (OR = 1.15, 95% CI = 0.83–1.58; I 2 = 14.8%; GRADE moderate) but not intracranial hemorrhage (OR = 1.01, 95% CI = 0.64–1.60; I 2 = 52.6%; GRADE low). Functional outcomes were not improved: Modified Rankin Scale (mRS) 0–1 (OR = 1.10, 95% CI = 0.83–1.46; I 2 = 60.5%; GRADE low) and mRS 0–2 (OR = 1.27, 95% CI = 0.89–1.80; I 2 = 73.4%; GRADE very low). Trial sequential analysis indicated evidence remains inconclusive. Agent-specific subgroup analyses suggested higher sICH with early aspirin (OR = 2.13, 95% CI = 1.02–4.45) and possible benefit for mRS 0–2 with tirofiban (OR = 2.07, 95% CI = 1.25–3.43). Conclusion: Routine early antiplatelet therapy within 24 h after IVT does not provide conclusive functional benefit, and our analysis cannot exclude clinically meaningful hemorrhagic harm. Further adequately powered RCTs are needed to define whether any selected regimen—especially tirofiban—has a favorable risk–benefit profile.

  • Efficacy and safety of pregabalin and duloxetine in painful diabetic neuropathy: a systematic review and meta-analysis

    by Ahmed Mansour, Ahmed Mostafa Amin, Ahmed Farid Gadelmawla, Ahmed Elbataa, Anas Mansour, Mohamed Ismail Elnady, Muhammad Ashraf Husain, Omar Abdulrahman Saad, Amr Elshahat, Abdallah Abbas, et al.

    Background and Objective: Pregabalin (PGB) and duloxetine (DLX) are commonly used first-line medications in the clinical management of painful diabetic neuropathy (PDN), yet high-quality comparative evidence is limited. This meta-analysis evaluates the comparative efficacy and safety of PGB versus DLX, focusing on efficacy outcomes such as pain reduction and mental health, and safety outcomes including adverse events in PDN patients. Method: We searched electronic databases for relevant studies assessing the efficacy and safety of PGB and DLX in PDN. The primary outcomes were the mean change of the Visual Analog Scale (VAS) and the improvement ratio for patients achieving ≥ 50% pain reduction. Secondary outcomes include the Numeric Rating Scale (NRS) for pain, the Short Form 12 Health Survey (SF-12), and related adverse events. A random-effects meta-analysis was performed to evaluate these outcomes. Results: We analyzed 19 studies involving 4483 patients. PGB significantly reduced VAS scores at 24 weeks (MD = -0.38; 95% confidence interval [CI], -0.45 to -0.31; P < .0001) and decreased the mental component of SF-12 compared to DLX (MD = -3.36; 95% CI, -6.64 to -0.07; P = .05) and lower rates of achieving >50% pain reduction (risk ratio = 0.88; 95% CI, 0.79 to 0.98; P = .03). Regarding safety, PGB showed a lower incidence of several adverse events, including anorexia, decreased appetite, diarrhea, nausea, and vomiting. However, no significant differences in VAS scores were observed between PGB and DLX at 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 12 weeks, with similar results observed in NRS. Conclusion: We found that PGB and DLX showed similar efficacy in relieving PDN. Ultimately, the 2 drugs’ similar effectiveness and different safety profiles highlight the importance of considering patient-specific factors when choosing the appropriate treatment.